TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05689944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance-therapy
Description: This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn of welcome and presentation of the upcoming session~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 15 mn of body warm-up with taught contemporary dance exercises~* 15 mn of creative research based on dance improvisation on a given theme~* 15 mn of sharing for the elaboration of a choreography~* At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session if he/she wishes (e.g. think of a choreography, remember what was done etc. ....) in order to encourage the commitment to care. These sessions will be based on contemporary dance and dance improvisation techniques.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art-therapy
Description: This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn of welcome and presentation of the upcoming session~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 10 mn of discovery of a new technique (acrylic painting or collage).~* 35 mn of practice in a project fixed beforehand~* At the end of the session, 5mn of self-evaluation of the pain, the thymia, the fatigue and the level of appreciation of the session (VNS).~After the session, the patient will be asked to think about the next session (e.g. collecting plants for collage....) in order to encourage commitment to the treatment. The sessions will be based on acrylic painting or collage techniques.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: This session will take place once a week between weeks 1 and 15 of the protocol.~* 5 mn welcome~* 5 mn of self-evaluation of the pain as well as of the thymia and the fatigue before the beginning of the session (Visual numerical scales: VNS)~* 50 mn of Vinyasa type yoga (warm-up, breathing, balance, strength and flexibility, relaxation)~* 5 mn of closing of the session~* At the end of the session, 5mn of self-evaluation of the pain thanks, the thymia, the fatigue and the level of appreciation of the session (VNS).~These sessions engage the body without entering into a therapy protocol turned towards art as in the two previous interventions.
Study: NCT03608631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
Description: Given IV
Study: NCT05832047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma solution (4-hour aggressive hydration)
Description: Aggressive hydration : 10 mL/kg injection within 30\~90min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30\~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer solution (4-hour aggressive hydration)
Description: Aggressive hydration : 10 mL/kg injection within 30\~90min before procedure, 3 mL/kg/hr fluid injection during procedure, 10 mL/kg injection within 30\~60min after procedure, fluid, injection at 3 mL/kg/hr for 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8-hour aggressive hydration
Description: If patients experienced postprocedural abdominal pain Numerical Rating Scale (NRS score\>3) or a worsening of abdominal pain compared with the pain before ERCP, the administration of study fluid continues until 8 hours (3 mL/kg/hr ) regardless of the results of serum amylase/lipase within 4 hours after ERCP because serum amylase/lipase within 4 hours after ERCP may have a result approximately 1-2 hours (5 hours-6 hours after ERCP) after blood sampling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8-hour aggressive hydration
Description: If patients experienced postprocedural abdominal pain Numerical Rating Scale (NRS score\>3) or a worsening of abdominal pain compared with the pain before ERCP, the administration of study fluid continues until 8 hours (3 mL/kg/hr ) regardless of the results of serum amylase/lipase within 4 hours after ERCP because serum amylase/lipase within 4 hours after ERCP may have a result approximately 1-2 hours (5 hours-6 hours after ERCP) after blood sampling
Study: NCT05644301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Oral capsule, 200 mg, twice daily, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Oral capsule, 200 mg, twice daily, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocyclin
Description: Oral capsule, 100 mg, twice daily, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocyclin
Description: Oral capsule, 100 mg, twice daily, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule, no active substance, twice daily, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule, no active substance, twice daily, for 12 weeks
Study: NCT06422247

Intervention type: DRUG
Intervention: Systemic therapy
Description: Approved peripheral T-cell lymphoma systemic treatments prescribed by the treating physician
Study: NCT06477029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tFUS
Description: tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tFUS
Description: tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tFUS
Description: Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tFUS
Description: Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
Study: NCT06479707

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Digital Literacy Intervention
Description: This intervention consists of 4-6 home visits with 3-4 interim phone calls based on the participant's individual digital literacy needs and goals. Each participant will receive internet connectivity (if not already available), a tablet (if not already available) and tailored action plans co-developed by the participant and the interventionist.
Study: NCT06217536

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Conventionally fractionated radiotherapy or external beam radiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-investigational surgery
Description: Non-investigational surgical procedure on tumor tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-investigational surgery
Description: Non-investigational surgical procedure on tumor tissue
Study: NCT06515106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote cognitive rehabilitation program
Description: Behavioral: Remote cognitive rehabilitation program Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
Study: NCT05135754

Intervention type: DEVICE
Group type: OTHER
Intervention: Heylo
Description: Test of the supporting product (test product) for a 12 weeks period. No additional intervention will be conducted. A few follow up nurse calls to assess few endpoints together with subject. All remaining endpoints are captured via surveys send to the subjects every 14 days.
Study: NCT05723263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Pay-it-forward
Description: 400 men who have sex with men (MSM) at 4 clinics will be enrolled. The standard pay-it-forward arm will include free point-of-care gonorrhea testing, as well as a passive community engagement component (such as viewing postcards and materials written by others encouraging gonorrhea/chlamydia testing).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Engaged Pay-it-forward
Description: 400 MSM at 4 clinics will be enrolled. The community engaged pay-it-forward arm will include free point-of-care gonorrhea testing, as well as an active community engagement component (such as multi-stakeholder co-creation activities to develop essential components of the intervention and implementation strategies; writing postcards; designing fans with stickers; sending out testing promotion messages on social media; and opportunity to donate to support others)

Intervention type: OTHER
Group type: OTHER
Intervention: Control arm
Description: 400 MSM at 4 clinics will be enrolled. The control arm will include a fee-based point-of-care gonorrhea testing (approximately 20 USD per test) and no community engagement component
Study: NCT06644326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100mg IkT-148009 Wet
Description: 100mg wet tablet formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200 mg Itraconazole
Description: 2 100mg capsules
Study: NCT06121570

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy (SLNB)
Description: A sample of the participant's tumor-draining lymph nodes will be collected and sent to the biotherapy center for LNL isolation and expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin will be administered at 100 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered at 30 mg/m\^2 IV daily for three days. Fludarabine will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-draining lymph node-derived lymphocyte (LNL)
Description: Participants receive single infusion of LNL at the recommended phase 2 dose (RP2D).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Eight to twelve hours after completing the LNL infusion, all participants will receive intermediate-dose decrescendo IL-2 IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered at 260 mg/m\^2 IV on Day 1 of Cycles 3-6 of the neoadjuvant chemotherapy of the study.
Study: NCT00986271

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EVLI was determinated by PiCCO plus system.
Study: NCT06107621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT for Gambling Disorder and psychiatric comorbidities
Description: The iCBT, is based on the gambling pathways model. As a clinical conceptualization, the treatment build on loss of control, but also include additional interventions (e.g., emotion regulation and impulse control) targeting the etiological co-morbidity factors in the pathways model for emotionally vulnerable and impulsive gamblers (pathways subtypes 2 and 3).
Study: NCT06217536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-investigational surgery
Description: Non-investigational surgical procedure on tumor tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-investigational surgery
Description: Non-investigational surgical procedure on tumor tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-investigational surgery
Description: Non-investigational surgical procedure on tumor tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-investigational surgery
Description: Non-investigational surgical procedure on tumor tissue
Study: NCT06353945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vaginal moisturizer
Description: vaginal moisturizer
Study: NCT06644326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100mg IkT-148009 Dry
Description: 100mg dry tablet formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50mg IkT-148009 Wet
Description: 50mg wet tablet formulation
Study: NCT06644885

Intervention type: PROCEDURE
Intervention: TIVAD implantation complications
Description: Follow up and post operative outcome of patients with devices implantation
Study: NCT06684769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emdogain® FL
Description: Enamel Matrix Derivatives

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Labrida BioClean®
Description: Oscillating Chitosan Brush
Study: NCT05975359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interi Manifold Drain System
Description: The Interi manifold surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the interi drain will be monitored daily and the Interi drain will remain in the surgical site until criteria for drain removal are met. Removal of the Interi drain will be performed in clinic by surgical staff.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jackson Pratt Drain System
Description: The Jackson Pratt surgical drain system will be placed in the breast pocket during stage 1 immediate implant based breast reconstruction. Output of the Jackson Pratt drain will be monitored daily and the drain will remain in the surgical site until criteria for drain removal are met. Removal of the Jackson Pratt drain will be performed in clinic by surgical staff.
Study: NCT06373068

Intervention type: OTHER
Intervention: Resuscitation orders
Description: Resuscitation orders, commonly referred to as Code Status, communicate to the healthcare team the specific medical interventions that patients will receive while hospitalised. These orders are issued by a doctor and require confirmation by at least one other licensed medical professional

Intervention type: OTHER
Intervention: Resuscitation orders
Description: Resuscitation orders, commonly referred to as Code Status, communicate to the healthcare team the specific medical interventions that patients will receive while hospitalised. These orders are issued by a doctor and require confirmation by at least one other licensed medical professional
Study: NCT06684769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labrida BioClean®
Description: Oscillating Chitosan Brush
Study: NCT06373068

Intervention type: OTHER
Intervention: Resuscitation orders
Description: Resuscitation orders, commonly referred to as Code Status, communicate to the healthcare team the specific medical interventions that patients will receive while hospitalised. These orders are issued by a doctor and require confirmation by at least one other licensed medical professional
Study: NCT05054439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: Si-b001 is administered by intravenous drip once a week (QW). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The dosage of paclitaxel was 80mg/m2 QW. SI-B001 and paclitaxel were used on the same day. After SI-B001 infusion, paclitaxel was pretreated and injected for no less than 3 hours.
Study: NCT05919030

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Description: Esophageal primary tumor: 39.6Gy/2.2Gy Bone metastasis: 30Gy/3Gy Lung, liver, brain metastases, metastatic lymph nodes: 45Gy/3Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg IV Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200 mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W
Study: NCT04013971

Intervention type: OTHER
Group type: OTHER
Intervention: AGRF Biofeedback Game
Description: During the AGRF biofeedback game participants will walk on a split-belt treadmill with a projector or screen display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game for 4 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: AGRF Biofeedback Game
Description: During the AGRF biofeedback game participants will walk on a split-belt treadmill with a projector or screen display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game for 4 minutes.
Study: NCT04879277

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: Plasmatic cytokine and plasmatic CRP assay will be realised using luminex in both arms. IL2, IL10,INF gamma, IL, IL6, ILB, TNF alpha will be analysed.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: Plasmatic cytokine and plasmatic CRP assay will be realised using luminex in both arms. IL2, IL10,INF gamma, IL, IL6, ILB, TNF alpha will be analysed.
Study: NCT04013971

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Biofeedback Interface
Description: For the traditional non-game biofeedback, the visual display comprises a horizontal line graph with a moveable cursor that represents the current measured value of antero-posterior ground reaction force for the targeted leg. The auditory feedback comprises an audible beep produced every time the cursor entered the target range. Participants will be exposed to the traditional biofeedback interface for 4 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Biofeedback Interface
Description: For the traditional non-game biofeedback, the visual display comprises a horizontal line graph with a moveable cursor that represents the current measured value of antero-posterior ground reaction force for the targeted leg. The auditory feedback comprises an audible beep produced every time the cursor entered the target range. Participants will be exposed to the traditional biofeedback interface for 4 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Condition
Description: Participants will complete a control walk with out feedback.
Study: NCT06418906

Intervention type: OTHER
Intervention: Self-reported questionnaires
Description: After participants agree to participate in this study, they will first fill out the set of questionnaires once. After two weeks, the research team will send them reminders to fill out the same set of questionnaires again.
Study: NCT04393103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid, 20% Intravenous Emulsion
Description: Atropine will be administered to ALL PATIENTS by doubling dose method which comprised of administering atropine start-ing from 2mg and to double the dose and administer till com-plete atropinization. Following this an infusion of 10-20% of the atropinizing dose was given every hour.~* Group A (Control Group) : Follow Up of 30 patients.~* Group B (Study Group): 30 patients will receive intralipid AS AN ADJUVANT Three boluses of IFE 15 mg/kg were given over 3 minutes, 20 minutes apart.
Study: NCT04013971

Intervention type: OTHER
Group type: OTHER
Intervention: Control Condition
Description: Participants will complete a control walk with out feedback.

Intervention type: OTHER
Group type: OTHER
Intervention: Optional Game with VR
Description: During the optional AGRF biofeedback game with virtual reality (VR) participants will walk on a split-belt treadmill with a head-mounted VR display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game with VR for 4 minutes.
Study: NCT05803772

Intervention type: DRUG
Group type: OTHER
Intervention: APHD-012
Description: Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)

Intervention type: DRUG
Group type: OTHER
Intervention: APHD-012
Description: Drug: APHD-012 Distal jejunal-release dextrose beads (Aphaia technology, AT)

Intervention type: DRUG
Group type: OTHER
Intervention: APH-012P
Description: Distal jejunal-release placebo beads

Intervention type: DRUG
Group type: OTHER
Intervention: APH-012P
Description: Distal jejunal-release placebo beads
Study: NCT03708809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrauterine system
Description: 13.5 mg levonorgestrel-releasing intrauterine system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrauterine system
Description: 13.5 mg levonorgestrel-releasing intrauterine system

Intervention type: OTHER
Group type: OTHER
Intervention: Alternative contraception to intrauterine system
Description: Alternative contraception including contraception pills, hormonal patches, hormonal vaginal , condomsring,